| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R43CA284999 | Development of a new class of BLVRB-targeted redox therapeutics in breast cancer | 000 | 1 | NIH | 1/8/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $898,408 ) |
| | 2023 | 2023 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R44HL150927 | Optimization of biliverdin IX? reductase redox inhibitors as novel reagents for enhancing platelet production | 000 | 3 | NIH | 8/10/2023 | $613,208 |
| | 2023 | 2023 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R43CA284999 | Development of a new class of BLVRB-targeted redox therapeutics in breast cancer | 000 | 1 | NIH | 9/14/2023 | $285,200 |
| | 2023 | 2020 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R43HL147793 | Detection of fetal platelets in maternal blood using platelet RNA biomarkers. | 000 | 1 | NIH | 12/6/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $763,993 ) |
| | 2022 | 2022 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R44HL150927 | Optimization of biliverdin IX? reductase redox inhibitors as novel reagents for enhancing platelet production | 001 | 2 | NIH | 6/9/2022 | $763,993 |
| | 2022 | 2021 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R44HL150927 | Optimization of biliverdin IX? reductase redox inhibitors as novel reagents for enhancing platelet production | 000 | 1 | NIH | 10/19/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $690,965 ) |
| | 2021 | 2021 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R44HL150927 | Optimization of biliverdin IX? reductase redox inhibitors as novel reagents for enhancing platelet production | 000 | 1 | NIH | 8/6/2021 | $690,965 |
|
| Issue Date FY: 2020 ( Subtotal = $272,302 ) |
| | 2020 | 2020 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R43HL147793 | Detection of fetal platelets in maternal blood using platelet RNA biomarkers. | 000 | 1 | NIH | 5/22/2020 | $272,302 |
| | 2020 | 2017 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R43AG059277 | HLS-Detection of RNA biomarkers in individual platelets | 000 | 1 | NIH | 9/20/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2017 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R43AG059277 | HLS-Detection of RNA biomarkers in individual platelets | 000 | 1 | NIH | 12/3/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2015 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R43HL129545 | Development of a biliverdin IX Beta reductase redox inhibitor for enhanced platelet production | 000 | 1 | NIH | 10/19/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $243,104 ) |
| | 2017 | 2017 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733-3038 | SUFFOLK | USA | R43AG059277 | HLS-Detection of RNA biomarkers in individual platelets | 000 | 1 | NIH | 9/10/2017 | $243,104 |
|
| Issue Date FY: 2015 ( Subtotal = $220,991 ) |
| | 2015 | 2015 | BLOOD CELL TECHNOLOGIES LLC | 9 SHIPYARD LN | SETAUKET | NY | 11733 | SUFFOLK | USA | R43HL129545 | Development of a biliverdin IX Beta reductase redox inhibitor for enhanced platelet production | 000 | 1 | NIH | 6/30/2015 | $220,991 |
|
|
